• Earlier in March 2026, Tempus AI, Inc. announced collaborations with Daiichi Sankyo to apply its PRISM2 multimodal AI to an oncology antibody-drug conjugate program and with Blood Cancer United to build a pediatric acute myeloid leukemia registry powered by its olivia app and Lens analytics platform.
• Together, these initiatives underline Tempus AI’s push to combine real-world data, clinical trial information, and patient-reported outcomes to refine biomarker discovery and patient stratification in cancer care.
• Next, we’ll examine how Tempus AI’s use of multimodal foundation models for oncology drug development could reshape its broader investment narrative.

Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

Tempus AI Investment Narrative Recap

To own Tempus AI, you need to believe its multimodal data and AI can translate hospital connectivity and pharma relationships into durable, higher margin data and diagnostics revenue, despite ongoing losses and reimbursement uncertainty. The Daiichi Sankyo and Blood Cancer United collaborations support this data centric thesis, but they do not clearly change the main near term swing factors: progress on reimbursement and evidence generation versus the risk that rising AI and compute spend keeps outpacing revenue.

Among the recent news, the Daiichi Sankyo collaboration looks most relevant for investors, because it directly tests whether Tempus’ multimodal foundation models, like PRISM2, can become embedded in oncology drug development workflows. If proof of concept models for antibody drug conjugate trials gain traction across Tempus’ database, that could inform how quickly pharma data contracts scale, relative to rising infrastructure costs and competitive pressure from larger AI and diagnostics players.

Yet even if these AI driven partnerships expand, investors still need to watch the growing compute and model spend that could quietly cap Tempus AI’s margins over time…

Tempus AI's narrative projects $2.3 billion revenue and $358.5 million earnings by 2029. This requires 22.0% yearly revenue growth and a $603.5 million earnings increase from -$245.0 million today.

Uncover how Tempus AI's forecasts yield a $77.93 fair value, a 83% upside to its current price.

Exploring Other Perspectives

More cautious analysts already assumed about 20.4% annual revenue growth and continued losses, and they worry that heavy foundation model spending may scale faster than commercial AI use cases.

Explore 13 other fair value estimates on Tempus AI - why the stock might be worth 22% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tempus AI research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.
• Find 61 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.